Fertility and Sterility
Volume 91, Issue 4 , Pages 1135-1140 , April 2009

Evaluation of the relationship between plasma concentrations of en- and zuclomiphene and induction of ovulation in anovulatory women being treated with clomiphene citrate

  • Cyrus Ghobadi, M.B.Ch.B.

      Affiliations

    • Academic Unit of Clinical Pharmacology, University of Sheffield, Sheffield, United Kingdom
    • Academic Unit of Reproductive and Developmental Medicine, University of Sheffield, Sheffield, United Kingdom
    • ,
  • Saad Amer, M.D.

      Affiliations

    • Academic Unit of Reproductive and Developmental Medicine, University of Sheffield, Sheffield, United Kingdom
    • ,
  • Hany Lashen, M.D.

      Affiliations

    • Academic Unit of Reproductive and Developmental Medicine, University of Sheffield, Sheffield, United Kingdom
    • ,
  • Martin S. Lennard, Ph.D.

      Affiliations

    • Academic Unit of Clinical Pharmacology, University of Sheffield, Sheffield, United Kingdom
    • ,
  • William L. Ledger, D.Phil.

      Affiliations

    • Academic Unit of Reproductive and Developmental Medicine, University of Sheffield, Sheffield, United Kingdom
    • ,
  • Amin Rostami-Hodjegan, Ph.D.

      Affiliations

    • Academic Unit of Clinical Pharmacology, University of Sheffield, Sheffield, United Kingdom
    • Corresponding Author InformationReprint requests: Amin Rostami-Hodjegan, Academic Unit of Clinical Pharmacology, Floor M, The Royal Hallamshire Hospital, Sheffield S10 2JF, United Kingdom (FAX: 44-114-2711863).

Received 25 December 2007 ,Revised 12 January 2008 ,Accepted 14 January 2008.

References 

  1. World Health Organization . WHO manual for the standardized investigation and diagnosis of the infertile couple. Cambridge, United Kingdom: Cambridge University Press; 1993;
  2. The ESHRE Capri Workshop Group. Anovulatory infertility. Hum Reprod. 1995;10:1549–1553
  3. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ. 2003;327:951–953
  4. Palomba S, Orio F, Zullo F. What is the best first-step therapeutic approach in treating anovulatory infertility in patients with polycystic ovary syndrome? Questions that are still unanswered. Gynecol Endocrinol. 2007;23:245–247
  5. Neveu N, Granger L, St-Michel P, Lavoie HB. Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction and achievement of pregnancy in 154 women with polycystic ovary syndrome. Fertil Steril. 2007;87:113–120
  6. Barbieri RL. Clomiphene versus metformin for ovulation induction in polycystic ovary syndrome: the winner is. J Clin Endocrinol Metab. 2007;92:3399–3401
  7. Palomba S, Orio F, Falbo A, Manguso F, Russo T, Cascella T, et al. Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:4068–4074
  8. Holzer H, Casper R, Tulandi T. A new era in ovulation induction. Fertil Steril. 2006;85:277–284
  9. Sturrock ND, Lannon B, Fay TN. Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. Br J Clin Pharmacol. 2002;53:469–473
  10. Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med. 2007;356:551–566
  11. Moll E, Bossuyt PM, Korevaar JC, Lambalk CB, van der Veen F. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ. 2006;332:1485
  12. Hughes E, Collins J, Vandekerckhove P. Clomiphene citrate for ovulation induction in women with oligo-amenorrhoea. Cochrane Database Syst Rev. 2000;(2):CD000056
  13. Imani B, Eijkemans MJ, Faessen GH, Bouchard P, Giudice LC, Fauser BC. Prediction of the individual follicle-stimulating hormone threshold for gonadotropin induction of ovulation in normogonadotropic anovulatory infertility: an approach to increase safety and efficiency. Fertil Steril. 2002;77:83–90
  14. Imani B, Eijkemans MJ, te Velde ER, Habbema JD, Fauser BC. Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J Clin Endocrinol Metab. 1998;83:2361–2365
  15. Imani B, Eijkemans MJ, te Velde ER, Habbema JD, Fauser BC. Predictors of chances to conceive in ovulatory patients during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J Clin Endocrinol Metab. 1999;84:1617–1622
  16. Imani B, Eijkemans MJ, te Velde ER, Habbema JD, Fauser BC. A nomogram to predict the probability of live birth after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Fertil Steril. 2002;77:91–97
  17. Dickey RP, Taylor SN, Curole DN, Rye PH, Lu PY, Pyrzak R. Relationship of clomiphene dose and patient weight to successful treatment. Hum Reprod. 1997;12:449–453
  18. Ruenitz PC. Rabbit liver microsomal metabolism of enclomiphene. Drug Metab Dispos. 1981;9:456–460
  19. Ruenitz PC, Arrendale RF, George GD, Thompson CB, Mokler CM, Nanavati NT. Biotransformation of the antiestrogen clomiphene to chemically reactive metabolites in the immature female rat. Cancer Res. 1987;47:4015–4019
  20. Ruenitz PC, Bagley JR, Mokler CM. Metabolism of clomiphene in the rat. Estrogen receptor affinity and antiestrogenic activity of clomiphene metabolites. Biochem Pharmacol. 1983;32:2941–2947
  21. Rostami-Hodjegan A, Lennard MS, Tucker GT, Ledger WL. Monitoring plasma concentrations to individualize treatment with clomiphene citrate. Fertil Steril. 2004;81:1187–1193
  22. Ernst S, Hite G, Cantrell JS, Richardson A, Benson HD. Stereochemistry of geometric isomers of clomiphene: a correction of the literature and a reexamination of structure-activity relationships. J Pharm Sci. 1976;65:148–150
  23. Tietz NW. Clinical guide to laboratory tests. Philadelphia: W.B. Saunders; 1995;
  24. Li TC, Spuijbroek MD, Tuckerman E, Anstie B, Loxley M, Laird S. Endocrinological and endometrial factors in recurrent miscarriage. BJOG. 2000;107:1471–1479
  25. Crewe HK, Ghobadi C, Gregory A, Rostami-Hodjegan A, Lennard MS. Determination by liquid chromatography-mass spectrometry of clomiphene isomers in the plasma of patients undergoing treatment for the induction of ovulation. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;847:296–299
  26. Hopke PK, Liu C, Rubin DB. Multiple imputation for multivariate data with missing and below-threshold measurements: time-series concentrations of pollutants in the Arctic. Biometrics. 2001;57:22–33
  27. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28:481–504
  28. Young SL, Opsahl MS, Fritz MA. Serum concentrations of enclomiphene and zuclomiphene across consecutive cycles of clomiphene citrate therapy in anovulatory infertile women. Fertil Steril. 1999;71:639–644
  29. Mikkelson TJ, Kroboth PD, Cameron WJ, Dittert LW, Chungi V, Manberg PJ. Single-dose pharmacokinetics of clomiphene citrate in normal volunteers. Fertil Steril. 1986;46:392–396
  30. Ghobadi C, Gregory A, Crewe HK, Rostami-Hodjegan A, Lennard MS. CYP2D6 is primarily responsible for the metabolism of clomiphene. Drug Metab Pharmacokinet. In press.
  31. Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007;101:113–121
  32. Beverage JN, Sissung TM, Sion AM, Danesi R, Figg WD. CYP2D6 polymorphisms and the impact on tamoxifen therapy. J Pharm Sci. 2007;96:2224–2231
  33. Crewe HK, Ellis SW, Lennard MS, Tucker GT. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol. 1997;53:171–178
  34. Dickinson GL, Rezaee S, Proctor NJ, Lennard MS, Tucker GT, Rostami-Hodjegan A. Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphism on pharmacokinetics and pharmacodynamics: dextromethorphan as a model application. J Clin Pharmacol. 2007;47:175–186

 C.G. has nothing to disclose. S.A. has nothing to disclose. H.L. has nothing to disclose. M.S.L. has nothing to disclose. W.L.L. has nothing to disclose. A.R.-H. has nothing to disclose.

 C.G. is a Ph.D. candidate, and the present work constitutes part of his thesis.

PII: S0015-0282(08)00153-2

doi: 10.1016/j.fertnstert.2008.01.058

Fertility and Sterility
Volume 91, Issue 4 , Pages 1135-1140 , April 2009

Article Tools

* Image Usage & Resolution